The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world patient characteristics and treatment patterns among cholangiocarcinoma patients treated with FGFR inhibitors.
 
Amit Mahipal
Consulting or Advisory Role - AstraZeneca/MedImmune; Elevar Therapeutics; Guardant Health; Taiho Oncology
Speakers' Bureau - AstraZeneca; Exelixis; Taiho Oncology
Research Funding - Taiho Pharmaceutical
 
Ruizhi Zhao
Employment - Taiho Oncology
Stock and Other Ownership Interests - Taiho Oncology (Inst)
 
Jon Tepsick
Employment - ConcertAI
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); EQRx (Inst); Gilead Sciences (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Regeneron (Inst); Sandoz (Inst); Taiho Pharmaceutical (Inst); TerSera (Inst)
 
Ziyu Lan
Research Funding - Novartis (Inst); Taiho Oncology (Inst)
 
Kathryn Penney
Research Funding - Taiho Oncology (Inst); Takeda (Inst)
 
Tehseen Salimi
No Relationships to Disclose